NorthWest Biotherapeutics Inc (NWBO)

[Chiugray]

GoodGuyBill, AI search was pretty helpful here. It confirmed to me the link and file is hosted on the NHS website and that it seems to be the "NHS England high cost drugs list 2025-2026" (version 20.0) document.

It seems to confirm what you are saying too:

This indicates:
1. The treatment has been approved, but only under IFR mechanisms, allowing funding on a case-by-case basis.
2. Murcidencel/DCVax-L is listed for tumor-based cancers generally, rather than restricted only to Glioblastoma.
_____

In the NHS context, it can be funded via IFR for various tumor-based cancers, not restricted to GBM. The decision to fund in a particular case would still depend on clinical justification and approval through the IFR process at the local Clinical Commissioning Group (CCG) or Integrated Care Board (ICB) level.

📌 Key Notes:
- IFR Funding Pathway: Murcidencel/DCVax-L is not routinely commissioned for widespread use across the NHS; it is considered a “Category 4” drug in the list—available via IFR only.
- Tumor-Agnostic Coverage: The listing does not limit it to GBM specifically, meaning it can be requested for other tumor-based cancers where there is a clinical rationale.
- Eligibility: The decision to approve funding would depend on the IFR panel’s assessment of clinical need, cost-effectiveness on a case-by-case basis, and adherence to IFR criteria.